Jun 1, 2026 08:01AM
Jun 1, 2026 08:00AM
Mar 9, 2026 05:35PM
Jan 23, 2026 12:56PM
Nov 10, 2025 10:01AM
Oct 1, 2025 01:20PM
Jul 20, 2025 08:00PM U.S. large biotech stocks Q2 earnings preview
Jan 27, 2025 07:50AM
Jan 24, 2025 07:33AM
Jan 13, 2025 12:50PM
Jan 12, 2025 05:01PM
Dec 19, 2024 01:40PM
Dec 19, 2024 06:00AM
Dec 19, 2024 06:00AM Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy
Nov 13, 2024 04:08PM
Nov 5, 2024 01:11PM
Nov 4, 2024 04:01PM
Oct 21, 2024 06:05AM
Oct 18, 2024 08:00AM
Oct 18, 2024 08:00AM
Sep 26, 2024 07:08AM Vertex Pharma (VRTX) Highlights First Oral Presentation of Phase 3 Clinical Data of the Vanza Triple and New Data on Long-Term Impact of TRIKAFTA
Sep 26, 2024 07:07AM
Aug 5, 2024 07:46AM
Aug 2, 2024 07:45AM
Aug 1, 2024 04:01PM
Jul 30, 2024 01:10PM
Jul 30, 2024 01:10PM
Jul 2, 2024 08:33AM Vertex Pharma (VRTX) Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for CF
Jul 2, 2024 08:33AM
Jan 16, 2024 02:24PM
Jan 16, 2024 02:24PM
Jan 8, 2024 05:26AM
Jan 7, 2024 03:00PM
Dec 12, 2023 03:21AM
Dec 11, 2023 07:30PM Positive Results from Pivotal Trials of CASGEVY™ (exagamglogene autotemcel) Highlighted in Oral Presentations at the American Society of Hematology (ASH) Annual Meeting and Exposition
Dec 8, 2023 12:55PM
Dec 8, 2023 12:52PM
Nov 16, 2023 04:53AM
Nov 16, 2023 01:45AM
Nov 6, 2023 04:01PM
Aug 1, 2023 04:01PM
Jun 9, 2023 05:35AM Vertex Pharma (VRTX) Announces FDA Acceptance of BLA for exagamglogene autotemcel for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
Jun 9, 2023 05:29AM
Jun 9, 2023 03:01AM
Jun 8, 2023 07:23PM
May 1, 2023 04:01PM
Feb 7, 2023 04:01PM
Aug 4, 2022 04:01PM
Feb 1, 2021 04:01PM Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
Jan 26, 2021 08:31AM

15,424 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All